{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:21Z","timestamp":1791315501415,"version":"4.3.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2023\/R\/1444"],"award-info":[{"award-number":["PSAU\/2023\/R\/1444"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["2023\/03\/25245"],"award-info":[{"award-number":["2023\/03\/25245"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000762","name":"Imperial College Healthcare NHS Trust","doi-asserted-by":"publisher","award":["FA1920_10"],"award-info":[{"award-number":["FA1920_10"]}],"id":[{"id":"10.13039\/501100000762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/11\/3\/28632"],"award-info":[{"award-number":["FS\/11\/3\/28632"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jtha.2024.03.024","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:05:01Z","timestamp":1712718301000},"page":"1867-1879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium"],"prefix":"10.1016","volume":"22","author":[{"given":"Ahmed","family":"Hjazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia Gonzalez","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Rodriguez-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Appiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ignat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golzar","family":"Mobayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.J.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.03.024_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2024.03.024_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib3","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.024_bib5","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.03.024_bib6","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtha.2024.03.024_bib8","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.024_bib10","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.03.024_bib11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance","volume":"103","author":"Ruschak","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtha.2024.03.024_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtha.2024.03.024_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ygcen.2011.02.005","article-title":"The role of ubiquitin-proteasome system in ageing","volume":"172","author":"L\u00f6w","year":"2011","journal-title":"Gen Comp Endocrinol"},{"key":"10.1016\/j.jtha.2024.03.024_bib15","first-page":"1562","article-title":"The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core","volume":"61","author":"Heinemeyer","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jtha.2024.03.024_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrm1049","article-title":"How the ubiquitin-proteasome system controls transcription","volume":"4","author":"Muratani","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jtha.2024.03.024_bib17","first-page":"137","article-title":"The ubiquitin-proteasome system","volume":"31","author":"Nandi","year":"2006","journal-title":"J\u00a0Biosci"},{"key":"10.1016\/j.jtha.2024.03.024_bib18","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.03.024_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2174\/138945009789577909","article-title":"Proteasome inhibitors in cancer therapy","volume":"10","author":"Testa","year":"2009","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jtha.2024.03.024_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.pharmtox.46.120604.141300","article-title":"The proteasome and proteasome inhibitors in cancer therapy","volume":"46","author":"Voorhees","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jtha.2024.03.024_bib22","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","article-title":"Proteasome inhibitors in cancer therapy: treatment regimen and peripheral neuropathy as a side effect","volume":"103","author":"Kaplan","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jtha.2024.03.024_bib24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in\u00a0vivo synergistic cytotoxicity in multiple myeloma","volume":"111","author":"Chauhan","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jtha.2024.03.024_bib27","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2217\/fon.15.123","article-title":"Carfilzomib for the treatment of patients with relapsed and\/or refractory multiple myeloma","volume":"11","author":"Stewart","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.03.024_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","article-title":"Clinical pharmacology of ixazomib: the first oral proteasome inhibitor","volume":"58","author":"Gupta","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2024.03.024_bib30","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/cancers12092540","article-title":"Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects","volume":"12","author":"Pancheri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2024.03.024_bib31","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.03.024_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)00145-5","article-title":"Carfilozomib versus bortezomib for relapsed or refractory myeloma \u2013 authors\u2019 reply","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib33","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2165\/11209010-000000000-00000","article-title":"Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma","volume":"72","author":"McCormack","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.03.024_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/cancers11050622","article-title":"Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy","volume":"11","author":"Bruno","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2024.03.024_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1573402114666180611110547","article-title":"Arterial hypertension and multiple myeloma: physiopathology and cardiovascular risk and \u2018practical\u2019 indications in\u00a0patients\u00a0receiving carfilzomib","volume":"15","author":"Milan","year":"2019","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.jtha.2024.03.024_bib36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/leu.2017.327","article-title":"Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma","volume":"32","author":"Bringhen","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtha.2024.03.024_bib37","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","article-title":"Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)","volume":"103","author":"Bringhen","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.03.024_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.03.024_bib39","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.03.024_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib41","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2024.03.024_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-019-0784-4","article-title":"Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management","volume":"21","author":"Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jtha.2024.03.024_bib43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib44","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1182\/blood-2014-01-547448","article-title":"The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)","volume":"123","author":"Nayak","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib45","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41409-020-0947-9","article-title":"The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium","volume":"55","author":"Martinez-Sanchez","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.03.024_bib46","doi-asserted-by":"crossref","first-page":"18210","DOI":"10.1074\/jbc.M112.355677","article-title":"Identification of intercellular cell adhesion molecule 1 (ICAM-1) as a hypoglycosylation marker in congenital disorders of glycosylation cells","volume":"287","author":"He","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.03.024_bib47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2012-02-410050","article-title":"O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions","volume":"120","author":"Nowak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.03.024_bib48","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtha.2024.03.024_bib49","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/dmd.112.047662","article-title":"Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib","volume":"41","author":"Wang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jtha.2024.03.024_bib50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/fon.11.42","article-title":"Carfilzomib: a novel second-generation proteasome inhibitor","volume":"7","author":"Khan","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtha.2024.03.024_bib51","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/0008-5472.CAN-13-2278","article-title":"Cancer cells exploit eIF4E2-directed synthesis of hypoxia response proteins to drive tumor progression","volume":"74","author":"Uniacke","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtha.2024.03.024_bib52","doi-asserted-by":"crossref","first-page":"441","DOI":"10.14348\/molcells.2017.0115","article-title":"Crosstalk and interplay between the ubiquitin-proteasome system and autophagy","volume":"40","author":"Ji","year":"2017","journal-title":"Mol Cells"},{"key":"10.1016\/j.jtha.2024.03.024_bib53","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/hmg\/ddi312","article-title":"Endoplasmic reticulum stress compromises the ubiquitin-proteasome system","volume":"14","author":"Men\u00e9ndez-Benito","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtha.2024.03.024_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022248118","article-title":"Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells","volume":"118","author":"Giri","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2024.03.024_bib55","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1161\/01.ATV.0000189309.05924.88","article-title":"Stimulated tissue plasminogen activator release as a marker of endothelial function in humans","volume":"25","author":"Oliver","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2024.03.024_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91700","article-title":"KLF2 and KLF4 control endothelial identity and vascular integrity","volume":"2","author":"Sangwung","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtha.2024.03.024_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157016112798829760","article-title":"The role of nitric oxide on endothelial function","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jtha.2024.03.024_bib58","doi-asserted-by":"crossref","first-page":"13769","DOI":"10.1074\/jbc.M700078200","article-title":"Kruppel-like factor 4 regulates endothelial inflammation","volume":"282","author":"Hamik","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2024.03.024_bib59","article-title":"The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.03.024_bib60","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1165\/rcmb.2011-0331OC","article-title":"Bortezomib alleviates experimental pulmonary arterial hypertension","volume":"47","author":"Kim","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtha.2024.03.024_bib61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1160\/TH05-07-0477","article-title":"Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator","volume":"95","author":"Zhang","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.03.024_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10741-011-9228-4","article-title":"Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies","volume":"17","author":"Tousoulis","year":"2012","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jtha.2024.03.024_bib63","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1089\/ars.2014.6158","article-title":"Central role of eNOS in the maintenance of endothelial homeostasis","volume":"22","author":"Heiss","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jtha.2024.03.024_bib64","first-page":"136","article-title":"Overexpression of eNOS decrease tissue factor (TF) level in CD34+ cells exhibit increased antithrombogenic property in small caliber vascular graft","volume":"60","author":"Wang","year":"2019","journal-title":"J\u00a0Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.jtha.2024.03.024_bib65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/CIRCRESAHA.108.174607","article-title":"Involvement of heat shock factor 1 in statin-induced transcriptional upregulation of endothelial thrombomodulin","volume":"103","author":"Fu","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2024.03.024_bib66","doi-asserted-by":"crossref","first-page":"59727","DOI":"10.18632\/oncotarget.10847","article-title":"Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation","volume":"7","author":"Shah","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtha.2024.03.024_bib67","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2353\/ajpath.2010.090316","article-title":"Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney","volume":"176","author":"Nakayama","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtha.2024.03.024_bib68","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bjh.18430","article-title":"Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment","volume":"199","author":"Yin","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.03.024_bib69","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jtha.2024.03.024_bib70","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41375-021-01141-4","article-title":"Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study","volume":"35","author":"Kastritis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtha.2024.03.024_bib71","doi-asserted-by":"crossref","first-page":"114907","DOI":"10.1016\/j.biopha.2023.114907","article-title":"BN Zordoky. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway","volume":"164","author":"Dabour","year":"2023","journal-title":"Biomed Pharmacother"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:10:06Z","timestamp":1762549806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1538783624001831"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.024","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. All rights reserved.","name":"copyright","label":"Copyright"}]}}